MRK

Merck & Company Inc
NYSEHEALTHCAREDRUG MANUFACTURERS - GENERAL

Key Statistics

Market Cap
$311.17B
P/E Ratio
36.41
EPS
$3.46
Beta
0.20
52W High
$130.29
52W Low
$74.18
50-Day MA
$117.66
200-Day MA
$107.92
Dividend Yield
2.55%
Profit Margin
13.60%
Forward P/E
25.06
PEG Ratio
6.26

About Merck & Company Inc

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$65.77B
Gross Profit (TTM)$50.46B
EBITDA$29.52B
Operating Margin38.60%
Return on Equity18.90%
Return on Assets12.60%
Revenue/Share (TTM)$26.42
Book Value$18.58
Price-to-Book6.83
Price-to-Sales (TTM)4.73
EV/Revenue5.42
EV/EBITDA18.37
Quarterly Earnings Growth (YoY)-19.30%
Quarterly Revenue Growth (YoY)4.90%
Shares Outstanding$2.47B
Float$2.47B
% Insiders0.06%
% Institutions82.14%

Historical Volatility

HV 10-Day
37.42%
HV 20-Day
32.41%
HV 30-Day
32.36%
HV 60-Day
31.13%
HV Rank
83.3%

Volatility is currently expanding

Analyst Ratings

Consensus ($131.67 target)
4
Strong Buy
15
Buy
9
Hold
1
Strong Sell

Latest News

Merck, AbbVie probed by US lawmakers over China clinical trials: report

A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country's military capabilities, according to a Reuters report. The inquiry, led by Republican Representative John Moolenaar of Michigan, chair of the House Select Committee on China, focuses on whether the drugmakers conducted adequate due diligence and maintained sufficient data protection standards at trial sites in China.

Proactive Investors6/30/2026Negative
Is Merck (MRK) a Buy as Wall Street Analysts Look Optimistic?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Zacks Investment Research6/29/2026Positive
The Big 3: JPM, DHR, MRK

Dan Deming talks joins today's Big 3 and highlights JPMorgan Chase (JPM) as shares touch new record highs. He sees Danaher (DHR) as a candidate for a continuing breakout, noting a similar pattern in Merck (MRK).

Schwab Network6/25/2026Positive

More HEALTHCARE Stocks

Data last updated: 7/9/2026